Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Document › Details

Domainex Ltd.. (2/13/20). "Press Release: Domainex Announces the Appointment of Tom Mander as Chief Executive Officer". Cambridge.

Organisations Organisation Domainex Ltd.
  Organisation 2 BioFocus (Group)
  Today Charles River (Group)
  Group Charles River (Group)
Products Product drug discovery services
  Product 2 small-molecule drug
Persons Person Mander, Thomas (Tom) (Domainex 202004– CEO joined 201504 as COO before Charles River + Asterand + Tripos UK + Evotec)
  Person 2 Perrior, Trevor (Domainex 201810–202003 CEO before CSO joined 2006 before Celltech + AZ RETIRED 3/20)

Domainex Ltd is pleased to announce the appointment of Dr Tom Mander as Chief Executive Officer. Dr Mander will take over when Dr Trevor Perrior retires from the role in April 2020. Tom has nearly 30 years of experience in small-molecule drug discovery, and joined Domainex as Chief Operating Officer in March 2015 with a mandate to achieve organic expansion of the drug discovery service business of the company.

Trevor Perrior, CEO of Domainex said: “I am very pleased that Tom has agreed to take over as Chief Executive. Tom joined the company with the remit of growing our business with global biotech and pharma companies and during the past five years of working together we have greatly expanded our strong service offering and built Domainex into a leading international CRO. I am confident that under Tom’s leadership Domainex will continue to grow and remain at the forefront of drug discovery technology providers”.

Commenting on his appointment, Tom Mander said “I’m delighted to be taking over as CEO of Domainex. It’s a privilege to work with all of our stakeholders and I am grateful to the Board for this opportunity to build on the company’s achievements. With over 40 clients and approximately 50% of our business coming from overseas clients, the last five years have marked our emergence as a global player in the drug discovery marketplace. With the exceptionally talented and dedicated team of scientists that we have assembled, I am confident that Domainex will continue to be an industry leader in the discovery of new medicines for our clients.”

Domainex’s Chairman Tony Brampton commented: “I would like to thank Trevor for 15 years of outstanding service. He joined Domainex as Research Director in 2006, was appointed CSO in 2016 and CEO in 2018. Under Trevor’s leadership, Domainex has built a superb reputation for conducting world-class science and driving its clients’ projects to the clinic. Domainex is fortunate that it will continue to benefit from Trevor’s expertise going forwards in a consultancy role.”

Tom Mander started his career at Amersham International, then became a senior scientist at Xenova before being appointed as a group leader managing high-throughput screening at Glaxo Wellcome. He has been involved in contract drug discovery for the past 21 years, holding operational, business development, and marketing roles at Evotec AG before taking executive management positions at Tripos Discovery Research (Vice President of Business Development) and Asterand (Vice President of Sales and Marketing) prior to their respective trade sales. Before joining Domainex, he was Director of Business Development in the Early Discovery division of Charles River, formerly BioFocus.


For more information contact:

Dr Tom Mander

Media Relations – Sciad Communications
Deborah Cockerill / Victoria Deaner / Sophie Protheroe
T: +44(0)20 3405 7892

Notes to Editors

About Domainex

Domainex is a leading integrated medicines research service partner working with ambitious life science organisations from around the globe. We have been setting new standards in research since 2001, working collaboratively with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions.

We provide innovative and customised biology and chemistry services to advance the disease research projects of our partners, from target expression to pre-clinical development candidate nomination. Working with Domainex maximises the chance of successful progression for our partners’ research and our approach consistently saves up to 30% of the time needed to discover new medicines by comparison with the industry average. Our innovative science and extensive technical capabilities enable us to produce novel medicines to treat diseases with strong commercial potential. We work closely and collaboratively with our sponsors to understand their aspirations, bringing our ideas, know-how and wealth of experience to bear on their projects.

Our highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges including being named on over 60 patent applications and the invention of numerous candidate drugs. We aim to deliver successful outcomes efficiently and quickly, setting the highest possible benchmark in medicines research.

Full information about Domainex and our award-winning services can be found at

Record changed: 2020-03-02


Picture [iito] Plain Stupid Simple 650x80px

More documents for Domainex Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top